5 completed, 4 terminated, 2 unknown, 1 withdrawn. 12 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 5, Terminated 4, Unknown 2, Withdrawn 1 |
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
Follow Glucagon-Like Peptide 1: new trials by email Literature Review of Glucagon-Like Peptide 1 trials Research Report on Glucagon-Like Peptide 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System Dasiglucagon, GlucaGen - Diabetes Mellitus, Type 1 | Phase 2 | Withdrawn | Inreda Diabetic B.V. | 2023-12-29 | 2024-01-03 | |
| Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon ZP4207, GlucaGen - Hypoglycemia | Phase 2 | Completed | Zealand Pharma | 81 | 2016-01-01 | 2016-06-15 |
| GLP-1 Loading During Elective Percutaneous Coronary Intervention GLP-1, placebo - Angina Pectoris, Myocardial Infarction | Phase 2 | Unknown | Papworth Hospital NHS Foundation Trust | 193 | 2015-03-01 | 2018-06-06 |
| Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus GLP-1, SC, Standard Medical Treatment - Type 2 Diabetes | Phase 1 / Phase 2 | Unknown | Diabetes Care Center of Nanjing Military Command | 100 | 2013-10-01 | 2014-02-20 |
| Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates glucagon like peptide-1, glucose control - Type 2 Diabetes | Phase 1 / Phase 2 | Terminated | Albert Einstein College of Medicine | 20 | 2010-08-12 | 2024-02-28 |
| Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET native glp-1 (7-36) - Healthy | Phase 2 / Phase 3 | Completed | University of Aarhus | 10 | 2010-06-01 | 2011-03-22 |
| Modulation of Human Myocardial Metabolism by GLP-1 Dose Response GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose - Type 2 Diabetes Mellitus, Healthy | Phase 2 / Phase 3 | Completed | Indiana University | 33 | 2010-05-01 | 2016-02-17 |
| Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients ROSE-010, Placebo - Irritable Bowel Syndrome Constipation Predominant | Phase 1 / Phase 2 | Completed | Mayo Clinic | 52 | 2010-01-01 | 2013-05-31 |
| The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients Glucagon-Like Peptide-1, Saline - Critically Ill, Hypoglycemia | Phase 2 | Terminated | Johns Hopkins University | 19 | 2008-12-01 | 2017-07-02 |
| Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone Insulin, Asp(B28)-, Glucagon, Placebo - Type 1 Diabetes | Phase 2 | Completed | Legacy Health System | 14 | 2008-11-01 | 2011-10-07 |
| Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery Placebo, GLP-1 (7-36) amide - CABG | Phase 2 | Terminated | Johns Hopkins University | 12 | 2008-09-01 | 2017-07-12 |
| The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition GLP-1 - Bariatric Surgery | Phase 2 | Terminated | Johns Hopkins University | 51 | 2007-05-01 | 2017-07-02 |
Diabetes Mellitus, Type 2 (3) · Hypoglycemia (3) · Diabetes Mellitus, Type 1 (2) · Insulin Resistance (2) · Angina Pectoris (1) · Constipation (1) · Coronary Disease (1) · Critical Illness (1) · Diabetes Mellitus (1) · Ichthyosis Bullosa of Siemens (1) · Irritable Bowel Syndrome (1) · Myocardial Infarction (1) · Reperfusion Injury (1)
Johns Hopkins University (3) · Albert Einstein College of Medicine (1) · Diabetes Care Center of Nanjing Military Command (1) · Indiana University (1) · Inreda Diabetic B.V. (1) · Legacy Health System (1) · Mayo Clinic (1) · Papworth Hospital NHS Foundation Trust (1) · University of Aarhus (1) · Zealand Pharma (1)
United States (7) · China (1) · Denmark (1) · Germany (1) · Netherlands (1) · United Kingdom (1)
Dariush Elahi, PhD (3) · Birgitte Brock, asso.prof. (1) · Daniel T Stein, MD (1) · G Laverman, MD (1) · Kieren J Mather, MD (1) · Michael Camilleri, MD (1) · Stephen Hoole, MA MD FRCP (1) · William K. Ward, MD (1) · Xiangjin Xu, Professor (1)
PMID 22517769, PMID 27143183, PMID 29273578, PMID 31277053
R01DK061644 (1), R21HL092799 (1), UL1RR024150 (1)